Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | WEE1 | P30291 | 1/20 | 0.37 |
| ▸ | TRPC6 | Q9Y210 | 4/20 | 0.37 |
| ▸ | USP25 | Q9UHP3 | 2/20 | 0.35 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.35 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13769026 | 0.84 | SCN9A (0.44) | ADRB1CHRNB2CHRNA4WEE1TRPC6 | |
| Hydrochloric Acid SCHEMBL28462986 | 0.83 | SCN9A (0.43) | ADRB1CHRNB2CHRNA4WEE1TRPC6 | |
| Hydrochloric Acid SCHEMBL28462985 | 0.83 | SCN9A (0.43) | ADRB1CHRNB2CHRNA4WEE1TRPC6 | |
| SCHEMBL22542075 | 0.80 | ADRB1 (0.47) | ADRB1PRKCQWEE1USP25USP28 | |
| SCHEMBL2819513 | 0.79 | CHRNB2 (0.47) | PRKCQCHRNB2CHRNA4 | |
| SCHEMBL22414247 | 0.79 | CHRNB2 (0.47) | PRKCQCHRNB2CHRNA4 | |
| SCHEMBL25949375 | 0.79 | CHRNB2 (0.47) | PRKCQCHRNB2CHRNA4 | |
| SCHEMBL21081153 | 0.79 | PRKCQ (0.39) | ADRB1PRKCQPIK3CAMTORTRPC6 | |
| SCHEMBL19231820 | 0.79 | LTA4H (0.49) | PRKCQ | |
| SCHEMBL21081117 | 0.78 | TRPC6 (0.47) | ADRB1PRKCQPIK3CAMTORTRPC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | ADRB1 1082/4885PRKCQ 293/4885CHRNB2 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.